Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
suitability of antihypertensive used. Always consider whether<br />
the medicine selected will exacerbate pre-existing conditions<br />
or interact with medicines the patient is already taking. 1<br />
If an ACE inhibitor is selected, consider choosing an<br />
alternative to cilazapril. New Zealand has high rates of<br />
cilazapril use, however, it is used much less commonly<br />
overseas. 8 As such, we are vulnerable to supply issues.<br />
PHARMAC has secured stock of cilazapril until 2022 but they<br />
cannot guarantee supplies beyond this point. 8 Supply of the<br />
fixed-dose combination of cilazapril with hydrochlorothiazide<br />
has been discontinued and stocks are expected to run out in<br />
September, <strong>2020</strong>. 8<br />
For more information on prescribing ACE inhibitors, see<br />
“Prescribing ACE inhibitors: time to reconsider old habits”,<br />
https://bpac.org.nz/2018/ace.aspx<br />
Beta-blockers are not first-line in patients with<br />
uncomplicated hypertension. Beta-blockers do not reduce<br />
the risk of stroke as much as other antihypertensive medicines<br />
and are often poorly tolerated. 1 However, beta-blockers<br />
may be preferred early in treatment for patients with some<br />
co-morbidities, such as ischaemic heart disease or atrial<br />
fibrillation. 1<br />
Use individualised BP targets<br />
A target BP of
Change language